

CEL SCI CORP
Form 10-Q
August 14, 2018

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q
(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE
ACT OF 1934

For the quarterly period ended June 30, 2018
OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT
OF 1934

For the transition period from _____ to _____.

Commission File Number 001-11889

CEL-SCI CORPORATION

Colorado 84-0916344
State or other jurisdiction incorporation (IRS) Employer Identification Number

8229 Boone Boulevard, Suite 802
Vienna, Virginia 22182
Address of principal executive offices

(703) 506-9460
Registrant's telephone number, including area code

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) had been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer" "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check One):

Edgar Filing: CEL SCI CORP - Form 10-Q

Large accelerated filer
Non-accelerated filer (Do not check if a smaller reporting company) Accelerated filer
Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act). Yes No

| Class of Stock | No. Shares Outstanding | Date |
|----------------|------------------------|----------------|
| Common | 23,541,703 | August 1, 2018 |

TABLE OF CONTENTS

PART I FINANCIAL INFORMATION

| Item 1. | Page |
|--|------|
| Condensed Balance Sheets at June 30, 2018 and September 30, 2017 (unaudited) | 3 |
| Condensed Statements of Operations for the nine months ended June 30, 2018 and 2017 (unaudited) | 4 |
| Condensed Statements of Operations for the three months ended June 30, 2018 and 2017 (unaudited) | 5 |
| Condensed Statements of Cash Flows for the nine months ended June 30, 2018 and 2017 (unaudited) | 6 |
| Notes to Condensed Financial Statements (unaudited) | 8 |
| Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations | 23 |
| Item 3. Controls and Procedures | 25 |
| PART II | |
| Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 26 |
| Item 6. Exhibits | 26 |
| Signatures | 27 |

CEL-SCI CORPORATION
 CONDENSED BALANCE SHEETS
 (UNAUDITED)

| | JUNE 30, | SEPTEMBER |
|--|--------------|--------------|
| | 2018 | 30, |
| ASSETS | | 2017 |
| Current Assets: | | |
| Cash and cash equivalents | \$2,346,650 | \$2,369,438 |
| Receivables | 119,652 | 218,481 |
| Prepaid expenses | 346,431 | 826,429 |
| Deposits - current portion | - | 150,000 |
| Inventory used for R&D and manufacturing | 628,158 | 672,522 |
| Total current assets | 3,440,891 | 4,236,870 |
| Plant, property and equipment, net | 16,361,651 | 16,793,220 |
| Patent costs, net | 227,166 | 223,167 |
| Deposits | 1,670,917 | 1,670,917 |
| Total Assets | \$21,700,625 | \$22,924,174 |
| LIABILITIES AND STOCKHOLDERS' DEFICIT | | |
| Current Liabilities: | | |
| Accounts payable | \$6,253,497 | \$8,196,334 |
| Accrued expenses | 861,842 | 936,698 |
| Due to employees | 1,242,813 | 693,831 |
| Notes payable | - | 994,258 |
| Derivative instruments, current portion | 4,916 | 10,984 |
| Other current liabilities | 14,290 | 12,449 |
| Total current liabilities | 8,377,358 | 10,844,554 |
| Derivative instruments, net of current portion | 1,076,400 | 2,042,418 |
| Lease liability | 13,336,969 | 13,211,925 |
| Deferred revenue | 126,795 | 125,000 |
| Other liabilities | 34,837 | 37,254 |

Edgar Filing: CEL SCI CORP - Form 10-Q

| | | |
|--|---------------------|---------------------|
| Total liabilities | 22,952,359 | 26,261,151 |
| Commitments and Contingencies | | |
| STOCKHOLDERS' DEFICIT | | |
| Preferred stock, \$.01 par value-200,000 shares authorized; -0- shares issued and outstanding | - | - |
| Common stock, \$.01 par value - 600,000,000 shares authorized; 19,570,468 and 11,903,133 shares issued and outstanding at June 30, 2018 and September 30, 2017, respectively | 195,706 | 119,031 |
| Additional paid-in capital | 315,217,502 | 296,298,401 |
| Accumulated deficit | (316,664,942) | (299,754,409) |
| Total stockholders' deficit | (1,251,734) | (3,336,977) |
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | \$21,700,625 | \$22,924,174 |

See notes to condensed financial statements.

CEL-SCI CORPORATION
 CONDENSED STATEMENTS OF OPERATIONS
 NINE MONTHS ENDED JUNE 30, 2018 and 2017
 (UNAUDITED)

| | 2018 | 2017 |
|--|----------------|---------------|
| Grant and other income | \$350,029 | \$51,822 |
| Operating Expenses: | | |
| Research and development | 7,713,873 | 13,307,275 |
| General & administrative | 5,823,694 | 4,347,830 |
| Total operating expenses | 13,537,567 | 17,655,105 |
| Operating loss | (13,187,538) | (17,603,283) |
| Gain on derivative instruments | 187,967 | 9,669,977 |
| Interest expense, net | (3,910,962) | (1,436,095) |
| Net loss available to common shareholders | \$(16,910,533) | \$(9,369,401) |
| Net loss per common share | | |
| Basic | \$(1.17) | \$(1.29) |
| Diluted | \$(1.17) | \$(1.34) |
| Weighted average common shares outstanding | | |
| Basic | 14,486,351 | 7,235,140 |
| Diluted | 14,486,351 | 7,292,715 |

See notes to condensed financial statements.

CEL-SCI CORPORATION
 CONDENSED STATEMENTS OF OPERATIONS
 THREE MONTHS ENDED JUNE 30, 2018 and 2017
 (UNAUDITED)

| | 2018 | 2017 |
|--|---------------|---------------|
| Grant and other income | \$104,170 | \$17,389 |
| Operating Expenses: | | |
| Research and development | 2,425,562 | 3,180,401 |
| General & administrative | 1,748,971 | 1,595,707 |
| Total operating expenses | 4,174,533 | 4,776,108 |
| Operating loss | (4,070,363) | (4,758,719) |
| (Loss) gain on derivative instruments | (8,618) | 790,365 |
| Interest expense, net | (1,935,587) | (495,709) |
| Net loss available to common shareholders | \$(6,014,568) | \$(4,464,063) |
| Net loss per common share | | |
| Basic and diluted | \$(0.36) | \$(0.53) |
| Weighted average common shares outstanding | | |
| Basic and diluted | 16,651,297 | 8,405,790 |

See notes to condensed financial statements.

CEL-SCI CORPORATION
 CONDENSED STATEMENTS OF CASH FLOWS
 NINE MONTHS ENDED JUNE 30, 2018 and 2017
 (UNAUDITED)

| | 2018 | 2017 |
|--|----------------|---------------|
| Net loss | \$(16,910,533) | \$(9,369,401) |
| Adjustments to reconcile net loss to net cash used in operating activities: | | |
| Depreciation and amortization | 485,710 | 476,103 |
| Share-based payments for services | 349,319 | 151,611 |
| Share-based payments for interest | 80,716 | - |
| Equity based compensation | 2,193,402 | 1,002,923 |
| Common stock contributed to 401(k) plan | 109,073 | 114,483 |
| Shares issued for settlement of clinical research costs | 2,957,400 | - |
| Loss on prepaid research and development | 471,157 | - |
| Loss on retired equipment | - | 1,187 |
| Gain on derivative instruments | (187,967) | (9,669,977) |
| Amortization of debt discount | 1,956,424 | 21,441 |
| Inducement expense | 291,234 | - |
| Capitalized lease interest | 125,044 | 149,209 |
| (Increase)/decrease in assets: | | |
| Receivables | 98,829 | (182,563) |
| Prepaid expenses | 122,627 | 275,084 |
| Inventory used for R&D and manufacturing | 44,364 | 350,904 |
| Deposits | 150,000 | 154,995 |
| Increase/(decrease) in liabilities: | | |
| Accounts payable | (1,960,438) | 5,514,909 |
| Accrued expenses | (74,856) | 555,250 |
| Due to employees | 548,982 | 103,013 |
| Other liabilities | 4,819 | 490 |
| Net cash used in operating activities | (9,144,694) | (10,350,339) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | | |
| Purchases of equipment | (1,015) | (10,525) |
| Expenditures for patent costs | (2,437) | - |
| Net cash used in investing activities | (3,452) | (10,525) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | | |
| Proceeds from issuance of common stock and warrants | 6,996,763 | 7,167,773 |
| Proceeds from issuance of notes payable | - | 1,510,000 |
| Proceeds from exercise of warrants | 2,133,677 | - |

Edgar Filing: CEL SCI CORP - Form 10-Q

| | | |
|--|-------------|-------------|
| Payments on obligations under capital lease | (5,082) | (2,428) |
| Net cash provided by financing activities | 9,125,358 | 8,675,345 |
| NET DECREASE IN CASH AND CASH EQUIVALENTS | (22,788) | (1,685,519) |
| CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD | 2,369,438 | 2,917,996 |
| CASH AND CASH EQUIVALENTS, END OF PERIOD | \$2,346,650 | \$1,232,477 |

See notes to condensed financial statements.

CEL-SCI CORPORATION
 CONDENSED STATEMENTS OF CASH FLOWS
 NINE MONTHS ENDED JUNE 30, 2018 and 2017

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

| | 2018 | 2017 |
|--|-------------|---------------|
| Decrease in receivable due under the litigation funding arrangement offset | | |
| by the same amount payable to the legal firm providing the services | \$- | \$305,341 |
| Capitalizable patent costs included in accounts payable | \$61,501 | \$11,586 |
| Capital lease obligation included in accounts payable | \$408 | \$2,266 |
| Property and equipment acquired through capital lease | \$- | \$26,104 |
| Fair value of warrants issued in connection with public offering | \$- | \$4,665,683 |
| Exercise of derivative liabilities | \$784,119 | \$- |
| Discount on notes payable | \$- | \$(1,205,647) |
| Financing costs included in accounts payable | \$- | \$92,467 |
| Prepaid consulting services paid with issuance of common stock | \$113,786 | \$(37,550) |
| Notes payable converted into common shares | \$2,294,300 | \$- |
| Conversion of accrued salaries and board fees to notes payable | \$- | \$250,000 |
| | | |
| Cash paid for interest expense | \$1,312,664 | \$1,413,455 |

See notes to condensed financial statements.

CEL-SCI CORPORATION
NOTES TO CONDENSED FINANCIAL STATEMENTS
PERIOD ENDED JUNE 30, 2018 AND 2017 (UNAUDITED)

A.
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company's annual report on Form 10-K for the year ended September 30, 2017.

In the opinion of management, the accompanying unaudited condensed financial statements contain all accruals and adjustments (each of which is of a normal recurring nature) necessary for a fair presentation of the Company's financial position as of June 30, 2018 and the results of its operations for the three and nine months then ended. The condensed balance sheet as of September 30, 2017 is derived from the September 30, 2017 audited financial statements. Significant accounting policies have been consistently applied in the interim financial statements and the annual financial statements. The results of operations for the nine and three months ended June 30, 2018 and 2017 are not necessarily indicative of the results to be expected for the entire year.

The financial statements have been prepared assuming the Company will continue as a going concern, but due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.

Summary of Significant Accounting Policies:

Research and Office Equipment and Leasehold Improvements - Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.

Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

Research and Development Costs - Research and development costs are expensed as incurred. Management accrues CRO expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company charges revisions to estimated expense in the period in

which the facts that give rise to the revision become known.

Income Taxes - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of June 30, 2018 and September 30, 2017.

On December 22, 2017, the “Tax Cuts and Jobs Act” (the “Tax Act”), was signed into law by the President of the United States (U.S.). The Tax Act includes significant changes to corporate taxation, including reduction of the U.S. corporate tax rate from 35% to 21%, effective January 1, 2018, limitation of the tax deduction for interest expense to 30% of earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks. The Company has accounted for certain income tax effects of the Act in applying FASB ASC 740 to the current reporting period. Because the Company records a valuation allowance for its entire deferred income tax asset, there was no impact to the amounts reported in the Company’s financial statements resulting from the Tax Act.

Derivative Instruments – The Company has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses recognized in earnings depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models and giving consideration to all of the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period.

Deferred Rent– Certain of the Company’s operating leases provide for minimum annual payments that adjust over the life of the lease. The aggregate minimum annual payments are expensed on a straight-line basis over the minimum lease term. The Company recognizes a deferred rent liability for rent escalations when the amount of straight-line rent exceeds the lease payments, and reduces the deferred rent liability when the lease payments exceed the straight-line rent expense. For tenant improvement allowances and rent holidays, the Company records a deferred rent liability and amortizes the deferred rent over the lease term as a reduction to rent expense.

Leases – Leases are categorized as either operating or capital leases at inception. Operating lease costs are recognized on a straight-line basis over the term of the lease. An asset and a corresponding liability for the capital lease obligation are established for the cost of capital leases. The capital lease obligation is amortized over the life of the lease. For build-to-suit leases, the Company establishes an asset and liability for the estimated construction costs incurred to the extent that it is involved in the construction of structural improvements or takes construction risk prior to the commencement of the lease. Upon occupancy of facilities under build-to-suit leases, the Company assesses whether these arrangements qualify for sales recognition under the sale-leaseback accounting guidance. If a lease does not meet the criteria to qualify for a sale-leaseback transaction, the established asset and liability remain on the Company’s balance sheet.

Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Compensation – Stock Compensation.” The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight line allocation method as expense over the requisite service or vesting period.

Equity instruments issued to non-employees are accounted for in accordance with ASC 505-50, “Equity-Based Payments to Non-Employees.” Accordingly, compensation is recognized when goods or services are received and is measured using the Black-Scholes valuation model. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the measurement date and the expected life of the options.

The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the stockholders.

The Company's stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company's stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.

Vesting of restricted stock granted under the Incentive Stock Bonus Plan is subject to service, performance and market conditions and meets the classification of equity awards. These awards were measured at market value on the grant-dates for issuances where the attainment of performance criteria is likely and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.

New Accounting Pronouncements

In June 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-07, Compensation—Stock Compensation (Topic 718), ("ASU 2018-7"), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). Under current GAAP, non-employee share-based payment awards are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever can be more reliably measured. Under ASU 2018-07, accounting for non-employee share-based payments would be consistent with the accounting requirement for employee share-based payment awards which requires non-employee share-based payments to be measured at grant-date fair value of the equity instruments an entity is obligated to issue when the good has been delivered or the service has been rendered and any other conditions necessary to earn the right to benefit from the instruments have been satisfied. Under current GAAP, the measurement date for equity classified non-employee share-based payment awards is the earlier of the date at which a commitment for performance by the counterparty is reached and the date at which the counterparty's performance is complete. Under ASU 2018-07, equity-classified nonemployee share-based payment awards are measured at the grant date. The definition of the term grant date is amended to generally state the date at which a grantor and a grantee reach a mutual understanding of the key terms and conditions of a share-based payment award. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity's adoption date of Topic 606. An entity should only remeasure liability-classified awards that have not been settled by the date of adoption and equity classified awards for which a measurement date has not been established through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. Upon transition, the entity is required to measure these non-employee awards at fair value as of the adoption date. The entity must not remeasure assets that are completed. The Company is currently evaluating the impact the adoption of the standard will have on the Company's financial position or results of operations.

In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 718), which affects any entity that changes the terms or conditions of a share-based payment award. This Update amends the definition of modification by qualifying that modification accounting does not apply to changes to outstanding share-based payment awards that do not affect the total fair value, vesting requirements, or equity/liability classification of the awards. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for (1) public business entities for reporting periods for which financial statements have not yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in this Update should be applied prospectively to an award modified on or after the adoption date. The Company adopted the provisions of ASU 2017-09 effective January 1, 2018. There was no impact on the financial position or results operations for the nine and three months ended June 30, 2018.

In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), and Derivative and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down-round features.

When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down-round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity's own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down-round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share ("EPS") in accordance with Topic 260 to recognize the effect of the down-round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down-round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Accounting Standards Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in Part I of this Update should be applied either retrospectively to outstanding financial instruments with a down-round feature by means of a cumulative-effect adjustment to the statement of financial position as of the beginning of the first fiscal year and interim period(s) in which the pending content that links to this paragraph is effective or retrospectively to outstanding financial instruments with a down-round feature for each prior reporting period presented in accordance with the guidance on accounting changes in paragraphs 250-10-45-5 through 45-10. The amendments in Part II of this Update do not require any transition guidance because those amendments do not have an accounting effect. The Company does not expect the adoption of this standard to have a significant impact on its EPS calculations, as it does not have any free-standing equity based financial instruments with down-round provisions.

In February 2016, the FASB issued ASU 2016-02, Leases, which will require most long-term leases to be recognized on the balance sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2018, but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning with the earliest comparative period presented. The Company is currently evaluating the impact the adoption of the standard will have on the Company's financial position or results of operations.

In March 2016, the FASB issued ASU 2016-09 Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The guidance simplified the accounting and financial reporting of the income tax impact of share-based compensation arrangements. This guidance requires excess tax benefits to be recorded as a discrete item within income tax expense rather than additional paid-in-capital. In addition, excess tax benefits are required to be classified as cash from operating activities rather than cash from financing activities. The Company adopted the provisions of ASU 2016-09 effective October 1, 2017. The Company elected to apply the cash flow guidance of ASU 2016-09 retrospectively to all prior periods with no impact to historical periods. The Company also adopted a change in accounting policy to recognize forfeitures of awards as they occur instead of estimating potential forfeitures with no material impact on historical periods.

The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

B.
OPERATIONS AND FINANCING

The Company has incurred significant costs since its inception for the acquisition of certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities, and clinical trials. The Company has funded such costs with proceeds from loans and the public and private sale of its common stock. The Company will be required to raise additional capital or find additional long-term financing in order to continue with its research efforts. To date, the Company has not generated any revenue from product sales. As a result, the Company has been dependent upon the proceeds from the sale of its securities to meet all of its liquidity and capital requirements and anticipates having to do so in the future. The ability of the Company to complete the necessary clinical trials and obtain US Food & Drug Administration (FDA) approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.

The Company is currently running a large multi-national Phase 3 clinical trial for head and neck cancer with its partners TEVA Pharmaceuticals and Orient Europharma. During the nine months ended June 30, 2018, the Company raised approximately \$7.0 million in net proceeds from private offerings and received proceeds of approximately \$2.1 million from the exercise of warrants. To finance the study beyond the next twelve months, the Company plans to raise additional capital in the form of corporate partnerships, debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine is a product in the Phase 3 clinical trial stage. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of funding, it may have to curtail its operations until it is able to raise the required funding. The financial statements have been prepared assuming the Company will continue as a going concern, but due to the Company's negative working capital, stockholders' deficit, recurring losses from operations and future liquidity needs, there is substantial doubt about the Company's ability to continue as a going

concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

As of June 30, 2018, the Company has incurred expenses of approximately \$49.5 million on direct costs for the Phase 3 clinical trial since its launch of the Phase 3 clinical trial for Multikine. The Company estimates it will incur additional expenses of approximately \$9.4 million for the remainder of the Phase 3 clinical trial. This estimate is based only on the information currently available in the Company's contracts with the Clinical Research Organizations responsible for managing the Phase 3 clinical trial and does not include other related costs, including manufacturing the drug. This number may be affected by the rate of death accumulation in the study, foreign currency exchange rates and many other factors, some of which cannot be foreseen today. It is therefore possible that the cost of the Phase 3 clinical trial will be higher than currently estimated. Nine hundred twenty-eight (928) head and neck cancer patients have been enrolled and have completed treatment in the Phase 3 study. The study end point is a 10% increase in overall survival of patients between the two main comparator groups in favor of the group receiving the Multikine treatment regimen. The determination if the study end point is met will occur when there are a total of 298 deaths in those two groups.

On October 31, 2013, the Company commenced arbitration proceedings against inVentiv Health Clinical, LLC, or inVentiv, its former clinical research organization (CRO), and now part of Syneos Health. The arbitration claim, initiated under the Commercial Rules of the American Arbitration Association, alleged (i) breach of contract, (ii) fraud in the inducement, and (iii) common law fraud. On June 25, 2018, the arbitrator ruled that inVentiv materially breached its contract with the Company and denied inVentiv all but one of its counterclaims (\$429,649 for certain unpaid invoices) against the Company. The arbitrator awarded the Company \$2,917,834 in damages. This is a final and binding decision and to the Company's knowledge, marks the first ever decision in favor of a pharmaceutical/biomedical company against a CRO for breach of contract. However, pursuant to the terms of an agreement with an affiliate of Lake Whillans Litigation Finance, LLC, a firm that produced partial funding for the legal expenses incurred by the Company in the arbitration proceedings, all amounts received from inVentiv by virtue of the arbitration award will be paid to Lake Whillans Litigation Finance. As a result of the arbitrator's ruling, the Company expensed a prepaid asset in the amount of approximately \$471,000, that will no longer be realized.

The Company's shareholders approved a reverse split of the Company's common stock which became effective on the NYSE American on June 15, 2017. On that date, every twenty-five issued and outstanding shares of the Company's common stock automatically converted into one outstanding share of common stock. As a result of the reverse stock split, the number of outstanding shares of common stock decreased from 230,127,331 (pre-split) shares to 9,201,645 (post-split) shares. The reduction in the number of outstanding shares resulted in an increase in the Company's loss per share by a factor of twenty-five, in all prior periods. The reverse stock split affected all stockholders of the Company's common stock uniformly, and did not affect any stockholder's percentage of ownership interest. The par value of the Company's stock remained unchanged at \$0.01 per share and the number of authorized shares of common stock remained the same after the reverse stock split.

C.
STOCKHOLDERS' EQUITY

Stock options, stock bonuses and compensation granted by the Company as of June 30, 2018 are as follows:

| Name of Plan | Total Shares Reserved Under Plans | Shares Reserved for Outstanding Options | Shares Issued | Remaining Options/Shares Under Plans |
|----------------------------------|-----------------------------------|---|---------------|--------------------------------------|
| Incentive Stock Options Plans | 138,400 | 123,558 | N/A | 385 |
| Non-Qualified Stock Option Plans | 3,387,200 | 2,946,606 | N/A | 399,533 |
| Stock Bonus Plans | 783,760 | N/A | 288,337 | 495,390 |
| Stock Compensation Plan | 134,000 | N/A | 118,590 | 15,410 |
| Incentive Stock Bonus Plan | 640,000 | N/A | 624,000 | 16,000 |

Stock options, stock bonuses and compensation granted by the Company as of September 30, 2017 are as follows:

| Name of Plan | Shares |
|--------------|--------|
|--------------|--------|

Edgar Filing: CEL SCI CORP - Form 10-Q

| | Total Shares Reserved Under Plans | Shares Reserved for Outstanding Options | Issued | Remaining Options/Shares Under Plans |
|-------------------------------------|--------------------------------------|--|---------|---|
| Incentive Stock Option Plans | 138,400 | 124,758 | N/A | 454 |
| Non-Qualified Stock Option Plans | 1,187,200 | 1,115,086 | N/A | 42,830 |
| Bonus Plans | 383,760 | N/A | 206,390 | 177,337 |
| Stock Compensation Plan | 134,000 | N/A | 115,590 | 18,410 |
| Incentive Stock Bonus Plan | 640,000 | N/A | 624,000 | 16,000 |

Stock option activity:

Nine Months Ended
June 30,

| | 2018 | 2017 |
|-----------|------------|--------|
| Granted | 1,858,1080 | 39,225 |
| Expired | 26,395 | 16,081 |
| Forfeited | 1,393 | 1,980 |

Three Months Ended
June 30,

| | 2018 | 2017 |
|-----------|-----------|--------|
| Granted | 1,847,808 | 39,225 |
| Expired | 2,016 | 800 |
| Forfeited | - | 919 |

Stock-Based Compensation Expense

Nine months Ended June
30,

| | 2018 | 2017 |
|---------------|-------------|-------------|
| Employees | \$2,193,402 | \$1,002,923 |
| Non-employees | \$349,319 | \$151,611 |

Three months Ended
June 30,

| | 2018 | 2017 |
|---------------|-----------|-----------|
| Employees | \$465,487 | \$325,168 |
| Non-employees | \$191,328 | \$38,833 |

Employee compensation expense includes the expense related to options issued or vested and restricted stock. The increase in employee compensation expense in 2018 is primarily due to an increase of approximately \$1 million in equity based compensation related to the Company's shareholder approved 2014 Incentive Stock Bonus Plan. Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of their service contracts. Stock based compensation expense is included in general and administrative expenses on the statements of operations.

Warrants and Non-employee Options

The following chart presents the outstanding warrants and non-employee options, listed by expiration date at June 30, 2018:

| Warrant | Issue Date | Shares Issuable upon Exercise of Warrants | Exercise Price | Expiration Date | Reference |
|---------|------------|---|----------------|-----------------|-----------|
|---------|------------|---|----------------|-----------------|-----------|

Edgar Filing: CEL SCI CORP - Form 10-Q

| | | | | | |
|-------------|-----------------------|-----------|-----------------|------------------|---|
| Series DD | 12/8/2016 | 1,360,960 | \$4.50 | 7/12/2018 | 1 |
| Series EE | 12/8/2016 | 1,360,960 | \$4.50 | 7/12/2018 | 1 |
| Series N | 8/18/2008 | 85,339 | \$3.00 | 8/18/2018 | * |
| Series S | 10/11/13- 10/24/14 | 327,729 | \$31.25 | 10/11/2018 | 1 |
| Series V | 5/28/2015 | 810,127 | \$19.75 | 5/28/2020 | 1 |
| Series UU | 6/11/2018 | 187,562 | \$2.80 | 6/11/2020 | 2 |
| Series W | 10/28/2015 | 688,930 | \$16.75 | 10/28/2020 | 1 |
| Series X | 1/13/2016 | 120,000 | \$9.25 | 1/13/2021 | * |
| Series Y | 2/15/2016 | 26,000 | \$12.00 | 2/15/2021 | * |
| Series ZZ | 5/23/2016 | 20,000 | \$13.75 | 5/18/2021 | 1 |
| Series BB | 8/26/2016 | 16,000 | \$13.75 | 8/22/2021 | 1 |
| Series Z | 5/23/2016 | 264,000 | \$13.75 | 11/23/2021 | 1 |
| Series FF | 12/8/2016 | 68,048 | \$3.91 | 12/1/2021 | 1 |
| Series CC | 12/8/2016 | 680,480 | \$5.00 | 12/8/2021 | 1 |
| Series HH | 2/23/2017 | 20,000 | \$3.13 | 2/16/2022 | 1 |
| Series AA | 8/26/2016 | 200,000 | \$13.75 | 2/22/2022 | 1 |
| Series JJ | 3/14/2017 | 30,000 | \$3.13 | 3/8/2022 | 1 |
| Series LL | 4/30/2017 | 26,398 | \$3.59 | 4/30/2022 | 1 |
| Series MM | 6/22/2017 | 893,491 | \$1.86 | 6/22/2022 | * |
| Series NN | 7/24/2017 | 539,300 | \$2.52 | 7/24/2022 | * |
| Series OO | 7/31/2017 | 60,000 | \$2.52 | 7/31/2022 | * |
| Series QQ | 8/22/2017 | 31,063 | \$2.50 | 8/22/2022 | 2 |
| Series GG | 2/23/2017 | 400,000 | \$3.00 | 8/23/2022 | 1 |
| Series II | 3/14/2017 | 600,000 | \$3.00 | 9/14/2022 | 1 |
| Series RR | 10/30/2017 | 583,057 | \$1.65 | 10/30/2022 | 2 |
| Series KK | 5/3/2017 | 395,970 | \$3.04 | 11/3/2022 | 1 |
| Series SS | 12/19/2017 | 1,013,162 | \$2.09 | 12/18/2022 | 2 |
| Series TT | 2/5/2018 | 1,875,860 | \$2.24 | 2/5/2023 | 2 |
| Series PP | 8/28/2017 | 1,674,500 | \$2.30 | 2/28/2023 | 2 |
| Consultants | 10/1/15- 7/28/17 | 36,400 | \$2.18- \$15.00 | 9/30/18- 7/27/27 | 3 |

*No current period changes to these warrants.

1.
Derivative Liabilities

The table below presents the warrant liabilities and their respective balances at the balance sheet dates:

| | June 30, 2018 | September 30, 2017 |
|---------------------------|------------------|-----------------------|
| Series S warrants | \$4,916 | \$32,773 |
| Series V warrants | 50,068 | 72,912 |
| Series W warrants | 65,276 | 83,754 |
| Series Z warrants | 42,534 | 77,216 |
| Series ZZ warrants | 2,651 | 4,753 |
| Series AA warrants | 36,750 | 65,087 |
| Series BB warrants | 2,334 | 4,322 |
| Series CC warrants | 212,976 | 394,220 |
| Series DD warrants | - | 5,492 |
| Series EE warrants | - | 5,492 |
| Series FF warrants | 24,035 | 47,154 |
| Series GG warrants | 172,042 | 342,173 |
| Series HH warrants | 8,052 | 16,014 |
| Series II warrants | 261,058 | 511,636 |
| Series JJ warrants | 12,233 | 24,203 |
| Series KK warrants | 175,912 | 345,720 |
| Series LL warrants | 10,479 | 20,481 |
| Total warrant liabilities | \$1,081,316 | \$2,053,402 |

The table below presents the gains and (losses) on the warrant liabilities for the nine months ended June 30:

| | 2018 | 2017 |
|--------------------|-------------|-------------|
| Series S Warrants | \$(756,261) | \$3,036,688 |
| Series V warrants | 22,842 | 1,450,126 |
| Series W warrants | 18,478 | 1,618,555 |
| Series Z warrants | 34,682 | 829,279 |
| Series ZZ warrants | 2,103 | 61,382 |
| Series AA warrants | 28,337 | 647,010 |
| Series BB warrants | 1,988 | 50,448 |
| Series CC warrants | 181,244 | 416,599 |
| Series DD warrants | 5,492 | 435,263 |
| Series EE warrants | 5,492 | 651,522 |
| Series FF warrants | 23,119 | 45,403 |

Edgar Filing: CEL SCI CORP - Form 10-Q

| | | |
|---------------------------------|-----------|-------------|
| Series GG warrants | 170,131 | 92,178 |
| Series HH warrants | 7,962 | 4,653 |
| Series II warrants | 250,578 | 137,044 |
| Series JJ warrants | 11,970 | 6,943 |
| Series KK warrants | 169,808 | 172,883 |
| Series LL warrants | 10,002 | 14,001 |
| Net gain on warrant liabilities | \$187,967 | \$9,669,977 |

The table below presents the gains and (losses) on the warrant liabilities for the three months ended June 30:

| | 2018 | 2017 |
|--|-------------|-----------|
| Series S Warrants | \$(768,188) | \$456,852 |
| Series V warrants | 26,389 | 32,405 |
| Series W warrants | 42,609 | 9,140 |
| Series Z warrants | 26,587 | 1,016 |
| Series ZZ warrants | 1,914 | 187 |
| Series AA warrants | 19,661 | 345 |
| Series BB warrants | 1,695 | 110 |
| Series CC warrants | 139,325 | (13,270) |
| Series DD warrants | 36 | 21,315 |
| Series EE warrants | 36 | 139,284 |
| Series FF warrants | 15,818 | (1,763) |
| Series GG warrants | 132,712 | (16,033) |
| Series HH warrants | 5,279 | (687) |
| Series II warrants | 199,970 | (24,375) |
| Series JJ warrants | 7,960 | (1,045) |
| Series KK warrants | 132,884 | 172,883 |
| Series LL warrants | 6,695 | 14,001 |
| Net gain (loss) on warrant liabilities | \$(8,618) | \$790,365 |

The Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument's contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company's stock because future equity offerings or sales of the Company's stock are not an input to the fair value of a "fixed-for-fixed" option on equity shares, and equity classification is therefore precluded.

In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting dates is recognized as a gain or loss in the accompanying statements of operations.

Changes in Liability Classified Warrants

On April 2, 2018, the exercise price of the Company's outstanding Series S warrants that are publicly traded under the symbol "CVM WS" on the NYSE American, was repriced to \$1.75 per share until June 11, 2018. After that date, the exercise price reverted back to \$31.25 per share of common stock. Warrant holders exercised 709,391 warrants under the temporarily revised terms, for total proceeds of approximately \$1.2 million. On January 12, 2018, the exercise price had been reduced to \$3.00 per share through April 3, 2018, however, no warrants were exercised under these terms. The modification was reflected in the fair value measurement of the warrants. Twenty-five (25) Series S warrants are required to purchase one share of common stock. The remaining Series S warrants expire on October 11, 2018.

On June 25, 2018, the Company extended the expiration date of its Series DD and Series EE warrants to July 12, 2018. On February 23, 2018, the Company extended the expiration date of these warrants to July 1, 2018. These

modifications were reflected in the fair value measurement of the warrants.

On October 17, 2017, 17,821 Series U warrants, with an exercise price of \$43.75, expired. The fair value of the Series U warrants was \$0 on the date of expiration.

On December 6, 2016, 105,000 Series R warrants, with an exercise price of \$100.00, expired. The fair value of the Series R warrants was \$0 on the date of expiration.

2.

Issuance of Equity Warrants

Series UU Warrants

On June 11, 2018, the Company issued 187,562 Series UU Warrants to holders of the outstanding Series MM and NN notes payable as an inducement to convert their notes into common stock (See Note F). The Series UU warrants are exercisable at a fixed price of \$2.80 per share, will not be exercisable for 6 months and expire on June 11, 2020.

Shares issuable upon the exercise of the warrants are restricted securities unless registered. The Company recognized an expense equal to the fair value of the consideration transferred in the transaction in excess of the fair value of consideration issuable under the original conversion terms. This expense represents the fair value of the Series UU warrants, which was calculated to be approximately \$291,000 and is included as interest expense on the statement of operations. The Series UU warrants qualify for equity treatment in accordance with ASC 815.

Series TT Warrants

On February 5, 2018, the Company sold 2,501,145 shares of its common stock at a price of \$1.87 per share for total proceeds of approximately \$4.7 million. The common stock was restricted unless registered. The purchasers of the common stock also received Series TT warrants which allow the purchasers to acquire up to 1,875,860 shares of the Company's common stock. The warrants are exercisable at a fixed price of \$2.24 per share, will not be exercisable for 6 months and one day and expire on February 5, 2023. Shares issuable upon the exercise of the warrants are restricted securities unless registered. The shares and warrants were registered on February 28, 2018. The Company allocated the proceeds received to the shares and the Series TT warrants on a relative fair value basis. As a result of such allocation, the Company determined the relative fair value of the Series TT warrants to be approximately \$1.56 million. The Series TT warrants qualify for equity treatment in accordance with ASC 815.

Series SS Warrants

On December 19, 2017 the Company sold 1,289,478 shares of its common stock at a price of \$1.90 per share for total proceeds of approximately \$2.45 million. The purchasers of the common stock also received Series SS warrants which allow the purchasers to acquire up to 1,289,478 shares of the Company's common stock. The warrants are exercisable at a fixed price of \$2.09 per share, and will expire on December 18, 2022. Shares issuable upon the exercise of the warrants will be restricted securities unless registered. The shares and warrants were registered on January 23, 2018. The Company allocated the proceeds received to the shares and the Series SS warrants on a relative fair value basis. As a result of such allocation, the Company determined the relative fair value of the Series SS warrants to be approximately \$1.0 million. The Series SS warrants qualify for equity treatment in accordance with ASC 815.

During the quarter ended June 30, 2018, 276,316 Series SS warrants were exercised for total proceeds of approximately \$578,000.

Series RR Warrants

On October 30, 2017, holders of convertible notes in the principal amount of \$1.1 million issued in June 2017 and holders of convertible notes in the principal amount of \$1.2 million issued in July 2017 agreed to extend the maturity date of these notes to September 21, 2018. In consideration for the extension of the maturity date of the convertible notes, the Company issued a total of 583,057 Series RR warrants to the convertible note holders that agreed to the extension. Each Series RR warrant entitles the holder to purchase one share of the Company's common stock. The Series RR warrants may be exercised at any time on or before October 30, 2022 at an exercise price of \$1.65 per share. The Series RR warrants were recorded at approximately \$0.7 million, the relative fair value on the date of issuance, as described in Note F.

Other Warrant Activity

During the quarter ended June 30, 2018, 75,500 Series PP warrants were exercised for total proceeds of approximately \$174,000 and 56,437 Series QQ warrants were exercised for total proceeds of approximately \$141,000.

3.

Options and shares issued to Consultants

The Company typically enters into consulting arrangements in exchange for common stock or stock options. During the nine and three months ended June 30, 2018, the Company issued 219,391 and 81,604 shares of common stock respectively, of which 216,391 and 78,604, respectively, were restricted shares. During the nine and three months

ended June 30, 2017, the Company issued 36,999 and 18,000 shares of common stock, respectively. The weighted average grant date fair value of the shares issued to consultants during the nine months ended June 30, 2018 and 2017, was \$2.11 and \$3.42 respectively. The aggregate values of the issuances of restricted common stock and common stock options are recorded as prepaid expenses and are charged to general and administrative expenses over the periods of service. If shares or options are issued for past services, the aggregate values are expensed when the shares or options are issued.

During the nine and three months ended June 30, 2018, the Company recorded total expense of approximately \$349,000 and \$191,000, respectively, relating to these consulting arrangements. During the nine and three months ended June 30, 2017, the Company recorded total expense of approximately \$152,000 and \$39,000, respectively, relating to these consulting arrangements. At June 30, 2018 and September 30, 2017, approximately \$159,000 and \$45,000, respectively, are included in prepaid expenses. As of June 30, 2018, the Company had 36,400 options outstanding, which were issued to consultants as payment for services. All of these options were vested and all were issued from the Non-Qualified Stock Option plans.

Other Equity Transactions

On May 16, 2018, the Company entered into a Securities Purchase Agreement with Ergomed plc, one of the Company's Clinical Research Organizations responsible for managing the Company's Phase 3 clinical trial, to facilitate a partial payment of the accounts payable balances due Ergomed. Under the Agreement, the Company issued Ergomed 600,000 shares, with a fair market value of approximately \$1.7 million, as a forbearance fee in exchange for Ergomed's agreement to provisionally forbear collection of the payables in an amount equal to the net proceeds from the resales of the shares issued to Ergomed. During the quarter ended June 30, 2018, the Company recorded the full amount of the expense upon issuance, offset by amounts realized through the resale by Ergomed of 462,921 shares for approximately \$0.7 million and the corresponding reduction of the payables resulting in a net expense of approximately \$1.0 million. As of June 30, 2018, Ergomed holds the remaining 137,079 shares and may resell the shares or return the shares to the Company for cancellation until December 31, 2018.

On January 1, 2018, and August 15, 2017, the Company entered into similar Securities Purchase Agreements with Ergomed plc, to facilitate a partial payment of the accounts payable balances due Ergomed. Under those Agreements, the Company issued Ergomed 660,000 and 480,000 shares, with a fair market value of approximately \$1.3 million and \$1.3 million, respectively, as a forbearance fee in exchange for Ergomed's agreement to provisionally forbear collection of the payables in an amount equal to the net proceeds from the resales of the shares issued to Ergomed.

During the nine months and three months ended June 30, 2018, the Company realized net interest expense of approximately \$0.2 million and \$0.1 million as a result of these Agreements.

D.
FAIR VALUE MEASUREMENTS

In accordance with ASC 820-10, "Fair Value Measurements," the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to those future amounts.

ASC 820-10 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:

Level 1 – Observable inputs such as quoted prices in active markets for identical assets or liabilities

Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets

Level 3 – Unobservable inputs that reflect management's assumptions

For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Company's assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at June 30, 2018:

| Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Total |
|---|---|---|-------|
|---|---|---|-------|

| | | | | |
|------------------------|---------|-----|-------------|-------------|
| Derivative instruments | \$4,916 | \$- | \$1,076,400 | \$1,081,316 |
|------------------------|---------|-----|-------------|-------------|

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2017:

| | Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Total |
|------------------------|---|---|---|-------------|
| Derivative instruments | \$32,773 | \$- | \$2,020,629 | \$2,053,402 |

The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) for the nine months ended June 30, 2018 and the year ended September 30, 2017:

| | 9 months ended | 12 months ended |
|-------------------------------|------------------|-----------------------|
| | June 30, 2018 | September 30, 2017 |
| Beginning balance | \$2,020,629 | \$5,283,573 |
| Issuances | - | 4,665,683 |
| Realized and unrealized gains | (944,229) | (7,928,627) |
| Ending balance | \$1,076,400 | \$2,020,629 |

The fair values of the Company's derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company's stock, as well as U.S. Treasury Bill rates, are observable in active markets.

E.

RELATED PARTY TRANSACTIONS

On June 22, 2017, CEL-SCI issued convertible notes (Series MM Notes) in the aggregate principal amount of \$1.5 million to six individual investors. Geert Kersten, the Company's Chief Executive Officer, participated in the offering and purchased a note in the principal amount of \$250,000. The terms of Mr. Kersten's note were identical to the other participants. On June 11, 2018, all outstanding Series MM Notes were converted into common stock. The number of shares of common stock issued upon conversion was determined by dividing the principal amount to be converted by \$1.69, which resulted in the issuance of 147,929 shares to Mr. Kersten. Along with the other purchasers of the convertible notes, upon issuance of the Series MM Notes, Mr. Kersten also received Series MM warrants to purchase up to 147,929 shares of the Company's common stock. The Series MM warrants are exercisable at a fixed price of \$1.86 per share and expire on June 22, 2022. Shares issuable upon the exercise of the notes and warrants were restricted securities unless registered. The shares were registered effective August 8, 2017.

On July 24, 2017, the Company issued convertible notes (Series NN) in the aggregate principal amount of \$1.2 million to twelve individual investors. A trust in which Mr. Kersten holds a beneficial interest participated in the offering and purchased a note in the principal amount of \$250,000. Patricia B. Prichep, the Company's Senior Vice President of Operations, participated in the offering and purchased a note in the principal amount of \$25,000. The terms of the trust's note and Ms. Prichep's note were identical to the other participants. On June 11, 2018, all outstanding Series NN Notes were converted into common stock. The number of shares of the Company's common stock issued upon conversion was determined by dividing the principal amount to be converted by \$2.29, which resulted in the issuance of 109,170 shares to the trust and 10,917 shares to Ms. Prichep. Along with the other purchasers of the convertible notes, upon issuance the trust and Ms. Prichep also received Series NN warrants to purchase up to 109,170 and 10,917 shares, respectively, of the Company's common stock. The Series NN warrants are exercisable at a fixed price of \$2.52 per share and expire on July 24, 2022. Shares issuable upon the exercise of the notes and warrants were restricted securities unless registered. The shares were registered effective September 1, 2017.

On June 11, 2018, to induce conversion of the Series MM and NN Notes, all note holders were given Series UU warrants in an amount equal to 20% of the shares into which the notes were convertible. This resulted in the issuance of 29,586, 21,834 and 2,183 Series UU warrants to Mr. Kersten, the trust and Ms. Prichep, respectively. The Series UU warrants have an exercise price of \$2.80 per share and expire on June 11, 2018 (See Note C). These terms are identical to the other recipients of the Series UU Warrants.

On October 30, 2017, the due dates of the Series NN and Series MM Notes were extended from December 22, 2017 to September 21, 2018 in exchange for Series RR warrants. Mr. Kersten, the trust and Ms. Prichep received 73,965, 54,585 and 5,459 Series RR warrants, respectively (See Note F). On June 30, 2018, there were no outstanding Series MM and Series NN Notes Payable.

The Series MM and NN Notes accrued interest at 4%. Upon conversion, the officers elected to receive the accrued interest in shares of common stock instead of cash. On the conversion date, the officers converted approximately \$19,000 in accrued interest into 6,930 shares of common stock.

F.
NOTES PAYABLE

The Series MM and Series NN Notes (collectively, the “Notes”) were issued in June and July 2017, as described in Note E. The Notes bear interest at 4% and could be converted into shares of the Company’s common stock at a fixed conversion rate of \$1.69 for the Series MM Notes and \$2.29 for the Series NN Notes. On October 30, 2017, the Company extended the due dates of the Notes from December 22, 2017 to September 21, 2018, and issued the note holders 583,057 of Series RR Warrants. The Series RR warrants expire on October 30, 2022 and are exercisable at a price of \$1.65 per share, which was the closing price of the Company’s common stock on October 27, 2017. These Series RR warrants are classified as equity warrants and are recorded at approximately \$0.7 million, the fair value on the date of issuance.

Because the Company was experiencing financial difficulties at the time of the modification and the creditors granted the Company a concession they would not have otherwise considered in the form of a lower effective interest rate, this modification was accounted for under ASC 470-60, "Troubled Debt Restructuring." The Company calculated the future cash flows of the restructured debt to be greater than the carrying value of the debt and accounted for the change in debt prospectively, using the effective interest rate that equated the carrying amount to the future cash flows. The carrying value of the debt on the date of restructuring was approximately \$0.7 million, which was net of a discount of approximately \$1.6 million. The discount is being amortized to interest expense over the life of the Notes using the effective interest method.

On June 11, 2018, all outstanding Series MM and Series NN notes were converted into common stock in accordance with the original agreements resulting in notes in the principal amount of \$1,860,000 being converted into 937,804 shares of common stock. As an inducement to convert, the Company issued the note holders 187,562 Series UU warrants. The Series UU warrants are exercisable at a fixed price of \$2.80 per share, are exercisable on December 11, 2018 and expire on June 11, 2020. Shares issuable upon the exercise of the warrants are restricted securities unless registered. The Company recognized an expense equal to the fair value of the consideration transferred in the transaction in excess of the fair value of consideration issuable under the original conversion terms. This expense represents the fair value of the Series UU warrants, which was calculated to be approximately \$291,000 and is included as interest expense on the statement of operations.

During the nine months ended June 30, 2018 and including the inducement, note holders converted notes in the principal amount of \$2,294,300, into 1,166,105 shares of common stock. During the three months ended June 30, 2018 and including the inducement, note holders converted notes in the principal amount of \$2,110,000, into 1,077,981 shares of common stock. The unamortized debt discounts relating to the converted Notes were charged to interest expense.

During the nine and three months ended June 30, 2018, the Company recorded approximately \$2.0 and \$1.0 million in interest expense, respectively, relating to the amortization of the debt discount. During the nine and three months ended June 30, 2017, the Company recorded approximately \$21,000 in interest expense, relating to the amortization of the debt discount.

On June 11, 2018, all note holders were given the option to receive the interest accrued on the Notes in cash or in shares converted at \$2.80, the fair value of the shares on that date. Accrued interest in the amount of approximately \$0.1 million was converted into 28,825 shares of common stock.

G. COMMITMENTS AND CONTINGENCIES

Clinical Research Agreements

In March 2013, the Company entered into an agreement with Aptiv Solutions, Inc. (which was subsequently acquired by ICON Inc.) to provide certain clinical research services in accordance with a master service agreement. The Company will reimburse ICON for costs incurred. The agreement required the Company to make \$600,000 in advance payments which are being credited against future invoices in \$150,000 annual increments through December 2017. As of June 30, 2018, all advance payments have been expensed.

In April 2013, the Company entered into a co-development and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to \$10 million towards the Company's Phase 3 Clinical Trial in the form of offering discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. In October 2015, the Company entered into a second co-development and revenue

sharing agreement with Ergomed for an additional \$2 million, for a total of \$12 million. The Company accounted for the co-development and revenue sharing agreement in accordance with ASC 808 “Collaborative Arrangements”. The Company determined the payments to Ergomed are within the scope of ASC 730 “Research and Development.” Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its Statements of Operations. Since the Company entered into the co-development and revenue sharing agreement with Ergomed, it has incurred research and development expenses of approximately \$27.4 million related to Ergomed’s services. This amount is net of Ergomed’s discount of approximately \$9.2 million. During the nine and three months ended June 30, 2018, the Company recorded, net of Ergomed’s discount, approximately \$2.4 million and \$0.8 million, respectively, as research and development expense related to Ergomed’s services. During the nine and three months ended June 30, 2017, the Company recorded, net of Ergomed’s discount, approximately \$5.1 million and \$1 million, respectively, as research and development expense related to Ergomed’s services.

Lease Agreements

The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company's specifications so that it can be used by the Company to manufacture Multikine for the Company's Phase 3 clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease. The Company contributed approximately \$9.3 million towards the tenant-directed improvements, of which \$3.2 million is being refunded during years nine through twenty through reduced rental payments. The landlord paid approximately \$11.9 million towards the purchase of the building, land and the tenant-directed improvements. The Company placed the building in service in October 2008.

The Company was deemed to be the owner of the building for accounting purpose under the build-to-suit guidance in ASC 840-40-55. In addition to tenant improvements the Company incurred, the Company also recorded an asset for tenant-directed improvements and for the costs paid by the lessor to purchase the building and to perform improvements, as well as a corresponding liability for the landlord costs. Upon completion of the improvements, the Company did not meet the "sale-leaseback" criteria under ASC 840-40-25, Accounting for Lease, Sale-Leaseback Transactions, and therefore, treated the lease as a financing obligation. Thus, the asset and corresponding liability were not de-recognized. As of June 30, 2018 and September 30, 2017, the leased building asset has a net book value of approximately \$16.2 and \$16.6 million, respectively, and the landlord liability has a balance of approximately \$13.3 and \$13.2 million, respectively. The leased building is being depreciated using a straight line method over the 20 year lease term to a residual value. Depreciation on the leased building was approximately \$0.4 million and \$0.1 million, respectively, for the nine and three months ended June 30, 2018 and 2017. Accumulated depreciation was approximately \$5.0 million and \$4.6 million as of June 30, 2018 and September 30, 2017, respectively. The landlord liability is being amortized over the 20 years using the effective interest method. Lease payments allocated to the landlord liability are accounted for as debt service payments on that liability using the finance method of accounting per ASC 840-40-55.

The Company was required to deposit the equivalent of one year of base rent in accordance with the lease. When the Company meets the minimum cash balance required by the lease, the deposit will be returned to the Company. The approximate \$1.7 million deposit is included in non-current assets at June 30, 2018 and September 30, 2017.

Approximate future minimum lease payments under the San Tomas lease as of June 30, 2018 are as follows:

| | |
|---|--------------|
| Three months ending September 30, 2018 | \$438,000 |
| Year ending September 30, | |
| 2019 | 1,808,000 |
| 2020 | 1,872,000 |
| 2021 | 1,937,000 |
| 2022 | 2,004,000 |
| 2023 | 2,073,000 |
| Thereafter | 11,685,000 |
| Total future minimum lease obligation | 21,817,000 |
| Less imputed interest on financing obligation | (8,480,000) |
| Net present value of lease financing obligation | \$13,337,000 |

The Company subleases a portion of its rental space on a month-to-month term lease, which requires a 30 day notice for termination. The Company receives approximately \$6,000 per month in rent for the sub-leased space.

The Company leases its research and development laboratory under a 60 month lease which expires February 28, 2022. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the full 60 month term of the lease at the rate of approximately \$13,000 per month. As of June 30, 2018 and September 30, 2017, the Company has recorded a deferred rent liability of approximately \$11,000 and \$5,000, respectively.

The Company leases its office headquarters under a 60 month lease which expires June 30, 2020. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight line basis over the full 60 month term of the lease at the rate approximately \$8,000 per month. As of June 30, 2018 and September 30, 2017, the Company has recorded a deferred rent liability of approximately \$15,000 and \$18,000, respectively.

As of June 30, 2018, material contractual obligations, excluding the San Tomas lease, consisting of non-cancelable operating lease payments are as follows:

| | |
|--|-----------|
| Three months ending September 30, 2018 | \$64,000 |
| Year ending September 30, | |
| 2019 | 258,000 |
| 2020 | 238,000 |
| 2021 | 163,000 |
| 2022 | 69,000 |
| Total | \$792,000 |

The Company leases office equipment under a capital lease arrangement. The term of the capital lease is 60 months and expires on October 31, 2021. The monthly lease payment is \$505. The lease bears interest at approximately 6.25% per annum.

H. PATENTS

During the nine and three months ended June 30, 2018 and 2017, no patent impairment charges were recorded. For the nine and three months ended June 30, 2018, amortization of patent costs totaled approximately \$53,000 and \$34,000, respectively. For the nine and three months ended June 30, 2017 amortization of patent costs totaled approximately \$30,000 and \$11,000, respectively. Approximate estimated future amortization expense is as follows:

| | |
|--|-----------|
| Three months ending September 30, 2018 | \$10,000 |
| Year ending September 30, | |
| 2019 | 38,000 |
| 2020 | 35,000 |
| 2021 | 32,000 |
| 2022 | 28,000 |
| 2023 | 18,000 |
| Thereafter | 66,000 |
| Total | \$227,000 |

I. LOSS PER COMMON SHARE

The following table provides the details of the basic and diluted loss per-share computations:

| | Nine months ended June 30, | | Three months ended June 30, | |
|---|----------------------------|---------------|-----------------------------|---------------|
| | 2018 | 2017 | 2018 | 2017 |
| Loss per share - basic | | | | |
| Net loss available to common shareholders - basic | \$(16,910,533) | \$(9,369,401) | \$(6,014,568) | \$(4,464,063) |
| Weighted average shares outstanding - basic | 14,486,351 | 7,235,140 | 16,651,297 | 8,405,790 |
| Basic loss per common share | \$(1.17) | \$(1.29) | \$(0.36) | \$(0.53) |

Edgar Filing: CEL SCI CORP - Form 10-Q

| | | | | |
|--|----------------|---------------|---------------|---------------|
| Loss per share - diluted | | | | |
| Net loss available to common shareholders - basic | \$(16,910,533) | \$(9,369,401) | \$(6,014,568) | \$(4,464,063) |
| Gain on derivatives (1) | - | (413,651) | - | - |
| Net loss available to common shareholders - diluted | \$(16,910,533) | \$(9,783,052) | \$(6,014,568) | \$(4,464,063) |
| | | | | |
| Weighted average shares outstanding - basic | 14,486,351 | 7,235,140 | 16,651,297 | 8,405,790 |
| Incremental shares underlying dilutive "in the money" warrants | - | 57,575 | - | - |
| Weighted average shares outstanding - diluted | 14,486,351 | 7,292,715 | 16,651,297 | 8,405,790 |
| Diluted loss per common share | \$(1.17) | \$(1.34) | \$(0.36) | \$(0.53) |

(1) Includes the net derivative gains from series GG, HH, II, JJ and KK warrants for the nine months ended June 30, 2017

The gain on derivatives priced lower than the average market price during the period is excluded from the numerator and the related shares are excluded from the denominator in calculating diluted loss per share.

In accordance with the contingently issuable shares guidance of FASB ASC Topic 260, Earnings Per Share, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of June 30:

| | 2018 | 2017 |
|---------------------------|------------|-----------|
| Options and Warrants | 12,567,982 | 7,951,929 |
| Unvested Restricted Stock | 312,000 | 604,000 |
| Convertible debt | - | 893,491 |
| Total | 12,879,982 | 9,449,420 |

J. SUBSEQUENT EVENTS

On July 2, 2018 the Company closed on a registered direct offering and concurrent private placement with institutional investors. The Company received gross proceeds of approximately \$5 million. The Company issued approximately 3,900,000 registered shares of common stock at a purchase price of \$1.30 per share. Concurrently in a private placement, the Company issued to the investors warrants to purchase up to 3,900,000 shares of its common stock. For each share of common stock purchased in the registered direct offering, the investors in the private placement received an unregistered warrant to purchase one share of common stock. The warrants have an exercise price of \$1.75 per share, will be exercisable upon the 6 month anniversary of the issue date, and will expire 5.5 years from the issue date.

On July 10, 2018 the Company extended the expiration date of its Series DD and Series EE warrants to December 10, 2018. The Series DD and Series EE warrants were issued on December 8, 2016.

On July 12, 2018, the Company received a letter from the NYSE American, its current listing exchange, which advised the Company that, based upon its March 31, 2018 10-Q report, the Company was noncompliant with the continued listing standards of the NYSE American. The Company can maintain its listing by submitting a plan of compliance by August 13, 2018. This plan must advise of actions the Company has taken or will take to regain compliance with the continued listing standards by January 14, 2019. The Company has already submitted such a plan. In addition, the NYSE American will not normally remove the securities of an issuer which is otherwise below the stockholders' equity continued listing criteria if the issuer has a market capitalization of at least \$50 million.

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Liquidity and Capital Resources

The Company's lead investigational therapy, Multikine® (Leukocyte Interleukin, Injection), is cleared for a Phase 3 clinical trial in advanced primary head and neck cancer. Multikine has been cleared by the regulators in twenty four countries around the world, including the U.S. FDA.

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this report as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved by the FDA or any other regulatory agency. Neither has its safety or efficacy been established for any use.

The Company also owns and is developing a pre-clinical technology called LEAPS (Ligand Epitope Antigen Presentation System).

All of the Company's projects are under development. As a result, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.

Since inception, the Company has financed its operations through the sale of equity securities, convertible notes, loans and certain research grants. The Company's expenses will continue to exceed its revenues as it continues the development of Multikine and brings other drug candidates into clinical trials. Until such time as the Company becomes profitable, any or all of these financing vehicles or others may be utilized to assist the Company's capital requirements.

Capital raised by the Company has been expended primarily for patent applications, research and development, administrative costs, and the construction of the Company's laboratory facilities. The Company does not anticipate realizing significant revenues until it enters into licensing arrangements regarding its technology and know-how or until it receives regulatory approval to sell its products (which could take a number of years). As a result the Company has been dependent upon the proceeds from the sale of its securities to meet all of its liquidity and capital requirements and anticipates having to do so in the future.

The Company will be required to raise additional capital or find additional long-term financing in order to continue with its research efforts. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company is taking cost-cutting initiatives, as well as exploring other sources of funding to finance operations over the next 12 months. However there can be no assurance that the Company will be able to raise sufficient capital to support its operations.

Since the Company launched its Phase 3 clinical trial for Multikine, the Company has incurred expenses of approximately \$49.5 million as of June 30, 2018 on direct costs for the Phase 3 clinical trial. The Company estimates it will incur additional expenses of approximately \$9.4 million for the remainder of the Phase 3 clinical trial. This estimate is based only on the information currently available in the Company's contracts with the Clinical Research Organizations responsible for managing the Phase 3 clinical trial and does not include other related costs, such as the manufacturing of the drug. This number may be affected by the rate of death accumulation in the study, foreign

currency exchange rates, and many other factors, some of which cannot be foreseen today. It is therefore possible that the cost of the Phase 3 clinical trial will be higher than currently estimated.

In April 2013, the Company announced that it had replaced the CRO running its Phase 3 clinical trial. This was necessary since the patient enrollment in the study dropped off substantially following a takeover of the CRO which caused most of the members of the CRO's study team to leave the CRO. The Company announced that it had hired two CRO's who will manage the global Phase 3 study; ICON and Ergomed, who are both international leaders in managing oncology trials. Both CRO's helped the Company expand the trial to over 80 clinical sites globally. The study is now fully enrolled with 928 patients.

Under a co-development agreement, Ergomed will contribute up to \$12 million towards the study where it will perform clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specified maximum amount, only from sales for head and neck cancer.

During the nine months ended June 30, 2018, the Company's cash remained constant. Cash used in operations of approximately \$9.1 million was offset by approximately \$9.1 million in cash provided by financing activities. Sources of financing during the nine months included approximately \$7.0 million in proceeds from the issuance of common stock and warrants and \$2.1 million in proceeds from the exercise of warrants. During the nine months ended June 30, 2017, the Company's cash decreased by approximately \$1.7 million. Significant components of this decrease include net proceeds from the sale of the Company's stock of approximately \$7.2 million and proceeds from the issuance of \$1.5 million in notes payable, offset by net cash used to fund the Company's regular operations, including its Phase 3 clinical trial, of approximately \$10.4 million.

On February 5, 2018, the Company sold 2,501,145 shares common stock at a price of \$1.87 for total proceeds of approximately \$4.6 million. The purchasers of the common stock also received Series TT warrants which allow the purchasers to acquire up to 1,875,860 shares of the Company's common stock. The warrants are exercisable on August 6, 2018 at a fixed price of \$2.24 per share and expire on February 5, 2023.

On December 19, 2017, the Company sold 1,289,478 shares of common stock at a price of \$1.90 for total proceeds of approximately \$2.45 million. The purchasers of the common stock received Series SS warrants which allow the purchasers to acquire 1,289,478 shares of the Company's common stock. The warrants are exercisable at a fixed price of \$2.09 per share, are exercisable on June 20, 2018 and will expire on December 18, 2022.

Inventory at June 30, 2018 remained constant, only decreasing by approximately \$44,000 as compared to September 30, 2017. In addition, receivables decreased by approximately \$99,000, primarily due to the timing of payments by the Company's partners for reimbursed clinical study costs related to the Phase 3 clinical trial.

Results of Operations and Financial Condition

During the nine and three months ended June 30, 2018, research and development expenses decreased by approximately \$5.6 million and \$0.8, respectively, compared to the nine and three months ended June 30, 2017. The majority of the Company's research and development expense relates to its on-going Phase 3 clinical trial. Clinical trial costs tend to be higher during the enrollment phase of the study and because the study is fully enrolled, the expenses incurred over the last nine months have decreased.

During the nine and three months ended June 30, 2018, general and administrative expenses increased by approximately \$1.5 million and \$0.2 million, respectively, compared to the nine and three months ended June 30, 2017. This increase over the nine month period is primarily due to an increase of approximately \$1.0 million in equity based compensation related to the Company's shareholder approved 2014 Incentive Stock Bonus Plan, and a net increase of approximately \$0.5 million in other general and administrative expenses primarily for accounting fees and public relations services. The increase over the three month period of approximately \$0.2 million related to net increases in other general and administrative expense primarily for public relations services.

The gain on derivative instruments of approximately \$0.2 million for the nine months ended June 30, 2018 and the de minimus loss for the three months ended June 30, 2018, respectively, were the result of the change in fair value of the derivative liabilities during the respective periods. These changes were caused by fluctuation in the share price of the Company's common stock. The gain on derivative instruments of approximately \$9.7 million and \$0.8 million, for the nine and three months ended June 30, 2017, respectively, were the result of the change in fair value of the derivative liabilities during the respective periods. These changes were caused by fluctuations in the share price of the Company's

common stock.

Net interest expense increased by approximately \$2.5 million for the nine months ended June 30, 2018 compared to the nine months ended June 30, 2017. The increase is primarily due to: 1) an increase of approximately \$2.0 million in amortization of discounts on notes payable issued in June and July 2017 and restructured in October 2017 and accrued interest on those notes; 2) the \$0.3 million inducement loss recorded on the conversion of the notes payable; and 3) the current period impact of the financing arrangement with Ergomed (as explained in Note C to the financial statements which are part of this report) which resulted in approximately \$0.2 million more in interest expense in 2018 over 2017. Net interest expense increased by approximately \$1.4 million for the three months ended June 30, 2018 compared to the three months ended June 30, 2017. The increase is primarily due to: 1) an increase of approximately \$1.0 million in amortization of discounts on notes payable issued in June and July 2017 and restructured in October 2017 and accrued interest on those notes; 2) the \$0.3 million inducement loss recorded on the conversion of the notes payable; and 3) the current period impact of the financing arrangement with Ergomed (as explained in Note C to the financial statements which are part of this report) which resulted in approximately \$0.1 million more in interest expense in 2018 over 2017.

Research and Development Expenses

The Company's research and development efforts during the nine months ended June 30, 2018 involved Multikine and LEAPS. The table below shows the research and development expenses associated with each project.

| | Nine months ended June 30, | | Three months ended June 30, | |
|-----------|-------------------------------|--------------|--------------------------------|-------------|
| | 2018 | 2017 | 2018 | 2017 |
| MULTIKINE | \$7,210,355 | \$13,041,970 | \$2,220,634 | \$3,091,298 |
| LEAPS | 503,518 | 265,305 | 204,928 | 89,103 |
| TOTAL | \$7,713,873 | \$13,307,275 | \$2,425,562 | \$3,180,401 |

Clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of the Company's clinical trials and research programs are primarily based upon the amount of capital available to the Company and the extent to which the Company has received regulatory approvals for clinical trials. The inability of the Company to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent the Company from completing the studies and research required to obtain regulatory approval for any products which the Company is developing. Without regulatory approval, the Company will be unable to sell any of its products. Since all of the Company's projects are under development, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.

Critical Accounting Estimates and Policies

Management's discussion and analysis of the Company's financial condition and results of operations is based on its unaudited condensed financial statements. The preparation of these financial statements is based on the selection of accounting policies and the application of significant accounting estimates, some of which require management to make judgments, estimates and assumptions that affect the amounts reported in the financial statements and notes. The Company believes some of the more critical estimates and policies that affect its financial condition and results of operations are in the areas of operating leases and stock-based compensation. For more information regarding the Company's critical accounting estimates and policies, see Part II, Item 7 of the Company's Annual Report on Form 10-K for the year ended September 30, 2017. The application of these critical accounting policies and estimates has been discussed with the Audit Committee of the Company's Board of Directors.

Item 3. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the direction and with the participation of the Company's management, including the Company's Chief Executive and Chief Financial Officer, the Company has conducted an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of June 30, 2018. The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic reports with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and regulations, and that such information is accumulated and communicated to the Company's management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. The Company's disclosure controls and procedures are designed

to provide a reasonable level of assurance of reaching its desired disclosure control objectives. Based on the evaluation, the Chief Executive and Chief Financial Officer concluded that the Company's disclosure controls and procedures were effective as of June 30, 2018.

Changes in Internal Control over Financial Reporting

The Company's management, with the participation of the Company's Chief Executive and Chief Financial Officer, has made changes to the Company's Internal Controls to address the material weaknesses as discussed in the Company's September 30, 2017 10-K, including the following:

All facility leasing activities are subject to a thorough review of capital versus operating lease classification. Further, leases that include construction activity prior to lease inception are reviewed against the build-to-suit lease guidance in ASC 840. In addition, the Company also engaged outside financial reporting specialists to assist it in the review process.

The Company enhanced its policy for reviewing long-lived assets for impairments by incorporating additional triggering event factors for consideration as part of its control. This review is carried out by the Company and also assisted by an outside financial reporting specialist.

The financial reporting process was enhanced to include the use of monthly, quarterly and annual closing checklists to capture routine and non-routine transactions that require additional review.

Further, the Company has also augmented its control process by expanding the use of a financial reporting specialist to assist in the financial close process.

PART II

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

During the nine months ended June 30, 2018 the Company issued 216,391 restricted shares of common stock to consultants for investor relations services.

The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 with respect to the issuance of these shares. The individuals who acquired these shares were sophisticated investors and were provided full information regarding the Company's business and operations. There was no general solicitation in connection with the offer or sale of these securities. The individuals who acquired these shares acquired them for their own accounts. The certificates representing these shares bear a restricted legend providing that they cannot be sold except pursuant to an effective registration statement or an exemption from registration. No commission or other form of remuneration was given to any person in connection with the issuance of these shares.

Item 6. Exhibits

Number Exhibit

31 Rule 13a-14(a) Certifications

32 Section 1350 Certifications

26

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CEL-SCI CORPORATION

Date: August 14, 2018 By: /s/ Geert Kersten
Geert Kersten
Principal Executive Officer*

* Also signing in the capacity of the Principal Accounting and Financial Officer.